NYSE · BRKR
Healthcare · Medical - Devices
$61.39
Down-$1.66 (-2.63%)
Updated Sep 20, 2026, 5:59 PM
SID Score
6.8/10
Composite research score
Smart Money
58/100
Neutral
Price performance
1M range · 19 trading sessions · Daily adjusted prices
BRKR closed at $61.39 after 19 trading sessions, up 7.74% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 18, 2026 | $63.37 | $63.49 | $60.40 | $61.39 | 2.82M |
| Sep 17, 2026 | $61.90 | $64.42 | $61.30 | $63.05 | 3.08M |
| Sep 16, 2026 | $56.64 | $61.72 | $56.61 | $60.67 | 4.11M |
| Sep 15, 2026 | $52.87 | $56.34 | $52.86 | $55.75 | 3.01M |
| Sep 14, 2026 | $53.11 | $53.615 | $51.54 | $52.66 | 2.78M |
| Sep 11, 2026 | $53.77 | $54.33 | $53.08 | $53.43 | 2.09M |
| Sep 10, 2026 | $53.21 | $54.31 | $52.58 | $53.56 | 1.88M |
| Sep 9, 2026 | $57.93 | $58.005 | $53.46 | $54.43 | 2.96M |
| Sep 8, 2026 | $57.58 | $58.57 | $56.80 | $58.37 | 1.04M |
| Sep 4, 2026 | $59.32 | $59.79 | $58.255 | $58.50 | 1.33M |
| Sep 3, 2026 | $59.82 | $60.29 | $57.47 | $59.41 | 1.21M |
| Sep 2, 2026 | $56.03 | $59.25 | $56.03 | $59.02 | 1.9M |
| Sep 1, 2026 | $57.79 | $58.00 | $55.66 | $56.03 | 2.03M |
| Aug 31, 2026 | $57.18 | $58.3627 | $56.03 | $58.01 | 1.86M |
| Aug 28, 2026 | $58.68 | $59.21 | $56.845 | $57.08 | 1.93M |
| Aug 27, 2026 | $58.13 | $59.515 | $57.605 | $59.25 | 2.43M |
| Aug 26, 2026 | $56.26 | $57.555 | $56.26 | $57.06 | 2.53M |
| Aug 25, 2026 | $57.38 | $58.19 | $56.00 | $56.85 | 1.63M |
| Aug 24, 2026 | $59.01 | $59.105 | $56.90 | $56.98 | 1.17M |
The latest Smart Investors Daily articles mentioning BRKR.
BRKR research
Company profile and research snapshot.
Bruker Corp manufactures scientific instruments and diagnostic tests for customers in the life sciences, applied markets, pharmaceutical, and biotechnology industries. The company operates in segments, namely, Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Supercon Technologies (BEST). The company generates maximum revenue from the BSI CALID segment. Geographically, it derives the maximum of its revenue from United States.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 9, 2026 | UBS | Neutral | — |
| Aug 5, 2026 | Citigroup | Neutral | — |
| Jul 8, 2026 | Citigroup | Neutral | — |
| Jul 7, 2026 | Leerink Partners | Outperform | — |
| Jun 29, 2026 | Guggenheim | Buy | — |
No generated briefing is available yet.
SeekingAlpha · Sep 16, 2026
Bruker Corporation (BRKR) Morgan Stanley 24th Annual Global Healthcare Conference September 16, 2026 10:45 AM EDTCompany ParticipantsFrank Laukien -...
Benzinga · Sep 16, 2026
U.S. stocks mixed as Nasdaq rises; LuxExperience jumps 13.5% on strong sales, while Einride, Forgent, Cipher and others post gains.
Yahoo · Sep 9, 2026
Shares of scientific instrument company Bruker (NASDAQ:BRKR) fell 6.3% in the afternoon session after UBS initiated coverage on the stock with a Neutral rating and a $65 price target.
Benzinga · Sep 9, 2026
UBS analyst Dan Leonard maintains Bruker (NASDAQ:BRKR) with a Neutral and raises the price target from $45 to $65.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning BRKR.
